Chen Saiya, Zhang Shengjing, Cai Shengsheng, Wang Huanfen
Department of Geriatric Medicine, Wenzhou TCM Hospital of Zhejiang Chinese Medical University, 9 Jiaowei Road, Wenzhou city, Zhejiang Province, 325000, China.
BMC Surg. 2024 Dec 27;24(1):419. doi: 10.1186/s12893-024-02728-1.
Coronary artery bypass grafting (CABG) remains the preferred treatment for complex multi-vessel coronary artery disease, offering substantial long-term benefits. Non-cardiac comorbidities such as frailty may significantly affect the outcomes of this procedure. However, the exact impact of frailty on CABG outcomes remains unclear, particularly given its exclusion from many pivotal revascularization trials. This systematic review and meta-analysis aimed to consolidate existing data to evaluate the impact of frailty on short- and long-term outcomes following CABG.
Searches across PubMed, Cochrane Library, Embase, and Scopus were done to identify studies that were published up to March 31, 2024, had detailed preoperative frailty assessments and compared frail versus non-frail adult patients undergoing CABG. Primary outcomes were all-cause mortality and major adverse cardiac events within one year. Secondary outcomes included hospital readmission rates and length of stay. A random-effects model was used to account for heterogeneity. Results were reported as odds ratios (OR) or mean differences (MD) with 95% confidence intervals (CI).
Our meta-analysis, involving data from 14 studies, revealed a significant increase in both 30-day (OR 2.52; 95% CI: 2.07 to 3.07) and 1-year mortality (OR 2.58; 95% CI: 1.49 to 4.45) among frail patients. The risk of acute cardiac and cerebrovascular complications was comparable in all patients (OR 1.03; 95% CI: 0.89 to 1.19). However, frailty was associated with a significant increase in the risk of acute kidney injury (OR 2.31; 95% CI: 1.26 to 4.23). Frail patients were more likely to have longer hospital stays and higher readmission rates compared to their non-frail counterparts.
Our study confirms the critical impact of frailty on mortality and morbidity in CABG patients and advocates for the integration of frailty assessments into the preoperative evaluation process. Addressing frailty can lead to more individualized patient care and better outcomes, urging a paradigm shift towards comprehensive, patient-centric management in cardiac surgery.
CRD42024521327.
冠状动脉旁路移植术(CABG)仍然是治疗复杂多支冠状动脉疾病的首选方法,具有显著的长期益处。诸如虚弱等非心脏合并症可能会显著影响该手术的结果。然而,虚弱对CABG结果的确切影响仍不清楚,特别是考虑到许多关键的血运重建试验都将其排除在外。本系统评价和荟萃分析旨在整合现有数据,以评估虚弱对CABG术后短期和长期结果的影响。
在PubMed、Cochrane图书馆、Embase和Scopus数据库中进行检索,以识别截至2024年3月31日发表的、具有详细术前虚弱评估且比较了接受CABG的虚弱与非虚弱成年患者的研究。主要结局是一年内的全因死亡率和主要不良心脏事件。次要结局包括医院再入院率和住院时间。采用随机效应模型来处理异质性。结果以比值比(OR)或均值差(MD)及95%置信区间(CI)的形式报告。
我们的荟萃分析纳入了14项研究的数据,结果显示虚弱患者30天死亡率(OR 2.52;95%CI:2.07至3.07)和1年死亡率(OR 2.58;95%CI:1.49至4.45)均显著增加。所有患者发生急性心脏和脑血管并发症的风险相当(OR 1.03;95%CI:0.89至1.19)。然而,虚弱与急性肾损伤风险显著增加相关(OR 2.31;95%CI:1.26至4.23)。与非虚弱患者相比,虚弱患者更有可能住院时间更长且再入院率更高。
我们的研究证实了虚弱对CABG患者死亡率和发病率的关键影响,并主张将虚弱评估纳入术前评估过程。解决虚弱问题可实现更个性化的患者护理并带来更好的结果,促使心脏手术向全面、以患者为中心的管理模式转变。
PROSPERO注册号:CRD42024521327。